Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017112860) DISTINGUISHING METASTATIC-LETHAL PROSTATE CANCER FROM INDOLENT PROSTATE CANCER USING METHYLATION STATUS OF EPIGENETIC MARKERS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/112860 International Application No.: PCT/US2016/068291
Publication Date: 29.06.2017 International Filing Date: 22.12.2016
IPC:
C12Q 1/68 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Q
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1
Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions
68
involving nucleic acids
Applicants:
FRED HUTCHINSON CANCER RESEARCH CENTER [US/US]; 1100 Fairview Avenue North Seattle, Washington 98109, US
Inventors:
STANFORD, Janet; US
FENG, Ziding; US
Agent:
WINGER, C. Rachal; US
WITTKOPP, Cristina; US
Priority Data:
62/387,27323.12.2015US
Title (EN) DISTINGUISHING METASTATIC-LETHAL PROSTATE CANCER FROM INDOLENT PROSTATE CANCER USING METHYLATION STATUS OF EPIGENETIC MARKERS
(FR) DIFFÉRENCIATION ENTRE UN CANCER MÉTASTATIQUE LÉTAL DE LA PROSTATE ET UN CANCER INDOLENT DE LA PROSTATE À L'AIDE DE L'ÉTAT DE MÉTHYLATION DE MARQUEURS ÉPIGÉNÉTIQUES
Abstract:
(EN) Methods and kits to distinguish metastatic-lethal prostate cancer (PCa) from indolent PCa in a subject are described. The methods and kits utilize the methylation status of genetic markers. Distinguishing metastatic-lethal PCa from indolent PCa informs more directed treatments at an earlier time point than previously available.
(FR) La présente invention concerne des méthodes et des kits permettant de différencier un cancer métastatique létal de la prostate (PCa) et un PCa indolent chez un sujet. Les méthodes et kits utilisent l'état de méthylation de marqueurs génétiques. La différenciation d'un PCa métastatique létal d'un PCa indolent fournit des informations sur des traitements plus ciblés à un stade plus précoce que précédemment.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
CN108474041US20190024184